Cargando…

Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol

The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, three diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Rani, Karina Citra, Parfati, Nani, Aryani, Ni Luh Dewi, Winantari, Agnes Nuniek, Fitriani, Endang Wahyu, Pradana, Aditya Trias, Nawatila, Roisah, Putranti, Astridani Rizky, Irine, Florencia, Angelica, Florentia, Yohanes, Cintya, Avanti, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537485/
https://www.ncbi.nlm.nih.gov/pubmed/34684021
http://dx.doi.org/10.3390/pharmaceutics13101727
_version_ 1784588262716735488
author Rani, Karina Citra
Parfati, Nani
Aryani, Ni Luh Dewi
Winantari, Agnes Nuniek
Fitriani, Endang Wahyu
Pradana, Aditya Trias
Nawatila, Roisah
Putranti, Astridani Rizky
Irine, Florencia
Angelica, Florentia
Yohanes, Cintya
Avanti, Christina
author_facet Rani, Karina Citra
Parfati, Nani
Aryani, Ni Luh Dewi
Winantari, Agnes Nuniek
Fitriani, Endang Wahyu
Pradana, Aditya Trias
Nawatila, Roisah
Putranti, Astridani Rizky
Irine, Florencia
Angelica, Florentia
Yohanes, Cintya
Avanti, Christina
author_sort Rani, Karina Citra
collection PubMed
description The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, three different types of film former including HPMC E5 4% (w/v), 5% (w/v), CMC-Na 3% (w/v), 4% (w/v), and Na-alginate 2.5% (w/v), 3% (w/v) were optimized in Formula 1 (F1) to Formula 6 (F6), respectively. A solvent casting method was employed to develop ODF of atenolol. The films formed by HPMC E5 produced a smooth and flexible surface, whereas CMC-Na and Na-alginate produced gritty textured films. Satisfactory results were obtained from several physical parameters such as film thickness, folding endurance, swelling index, and disintegration time. The homogeneity, drug content, and dissolution properties of ODF with HPMC exhibited better characteristics than the other formulas. Formula 1 exhibited the highest drug release compared to the other ODFs. The molecular docking results showed that there was a hydrogen bonding between atenolol and film formers which was also supported by the FTIR spectrum. The findings of this study suggest that HPMC E5 is the most favorable film former for ODF of atenolol.
format Online
Article
Text
id pubmed-8537485
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85374852021-10-24 Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol Rani, Karina Citra Parfati, Nani Aryani, Ni Luh Dewi Winantari, Agnes Nuniek Fitriani, Endang Wahyu Pradana, Aditya Trias Nawatila, Roisah Putranti, Astridani Rizky Irine, Florencia Angelica, Florentia Yohanes, Cintya Avanti, Christina Pharmaceutics Article The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, three different types of film former including HPMC E5 4% (w/v), 5% (w/v), CMC-Na 3% (w/v), 4% (w/v), and Na-alginate 2.5% (w/v), 3% (w/v) were optimized in Formula 1 (F1) to Formula 6 (F6), respectively. A solvent casting method was employed to develop ODF of atenolol. The films formed by HPMC E5 produced a smooth and flexible surface, whereas CMC-Na and Na-alginate produced gritty textured films. Satisfactory results were obtained from several physical parameters such as film thickness, folding endurance, swelling index, and disintegration time. The homogeneity, drug content, and dissolution properties of ODF with HPMC exhibited better characteristics than the other formulas. Formula 1 exhibited the highest drug release compared to the other ODFs. The molecular docking results showed that there was a hydrogen bonding between atenolol and film formers which was also supported by the FTIR spectrum. The findings of this study suggest that HPMC E5 is the most favorable film former for ODF of atenolol. MDPI 2021-10-19 /pmc/articles/PMC8537485/ /pubmed/34684021 http://dx.doi.org/10.3390/pharmaceutics13101727 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rani, Karina Citra
Parfati, Nani
Aryani, Ni Luh Dewi
Winantari, Agnes Nuniek
Fitriani, Endang Wahyu
Pradana, Aditya Trias
Nawatila, Roisah
Putranti, Astridani Rizky
Irine, Florencia
Angelica, Florentia
Yohanes, Cintya
Avanti, Christina
Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol
title Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol
title_full Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol
title_fullStr Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol
title_full_unstemmed Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol
title_short Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol
title_sort development, evaluation, and molecular docking of oral dissolving film of atenolol
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537485/
https://www.ncbi.nlm.nih.gov/pubmed/34684021
http://dx.doi.org/10.3390/pharmaceutics13101727
work_keys_str_mv AT ranikarinacitra developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT parfatinani developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT aryaniniluhdewi developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT winantariagnesnuniek developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT fitrianiendangwahyu developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT pradanaadityatrias developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT nawatilaroisah developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT putrantiastridanirizky developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT irineflorencia developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT angelicaflorentia developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT yohanescintya developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol
AT avantichristina developmentevaluationandmoleculardockingoforaldissolvingfilmofatenolol